Benralizumab
ApprovedCompleted 0 watching 0 views this week๐ฅ Hot
85
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Asthma
Conditions
Asthma
Trial Timeline
Sep 30, 2019 โ Apr 23, 2024
NCT ID
NCT04102800About Benralizumab
Benralizumab is a approved stage product being developed by AstraZeneca for Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT04102800. Target conditions include Asthma.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (18)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07444567 | Phase 3 | Recruiting |
| NCT07214753 | Pre-clinical | Recruiting |
| NCT06512883 | Phase 3 | Recruiting |
| NCT06465485 | Phase 3 | Active |
| NCT05273359 | Phase 2 | UNKNOWN |
| NCT05384938 | Approved | Completed |
| NCT05932849 | Pre-clinical | Completed |
| NCT04305405 | Phase 3 | Completed |
| NCT04102800 | Approved | Completed |
| NCT03928262 | Phase 1 | Completed |
| NCT03557307 | Phase 3 | Completed |
| NCT03327701 | Phase 3 | UNKNOWN |
| NCT03010436 | Phase 2 | UNKNOWN |
| NCT02918071 | Phase 3 | Completed |
| NCT02869438 | Phase 3 | Completed |
| NCT02821416 | Phase 3 | Completed |
| NCT02417961 | Phase 3 | Completed |
| NCT02130882 | Phase 2/3 | UNKNOWN |
Competing Products
20 competing products in Asthma